Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPrince of Songkla University
About this trial
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
Eligibility criteria
Qualifiers
Diagnosis of neovascular glaucoma
The patients having IOP > 21 mmHg, having the indication for trabeculectomy
The patients' age of at least 18-year-old
The patients having visual potential at least hand motion.
Disqualifiers
One eye patient
Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
Cannot obtain endothelial cell count.
History of bevacizumab or fluorescence dye allergy.
Trial design
Treatments tested in this trial
- Intracameral injection
- Intravitreal injection
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov